NUVL FY2025 SEC EDGAR DEF 14A #126 of 168 in industry

Nuvalent, Inc. CEO pay ratio

The CEO earned $540K in FY2025 against median worker pay of $540,474 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#126/168

Data updated August 2026

Subscribe to Nuvalent, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
21:1
Below Average (Scale: 0–1000:1)
CEO pay
$540K
Median worker
$540,474

Answer first

Nuvalent, Inc.'s FY2025 CEO total of $540K ranks #1278 of 1,423 complete filings; its 21:1 pay ratio ranks #1209. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $540,474. Industry placement uses the FY2025 SIC-28 peer cohort (# 126 of 168, 26th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1278
$540K of 1,423 FY2025
Ratio rank
#1209
21:1 of 1,423
Industry pct
26th
below the industry median pay ratio

How Nuvalent, Inc. ranks nationally

Nuvalent, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$540,474 10th percentile higher than 10% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Nuvalent, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($540K) against pay ratio (21:1) for Nuvalent, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02253862.04507724.16761586.19015448.217.9:124.2:130.5:136.8:143.1:1CEO total payPay ratio (CEO : median worker)Nuvalent, Inc., CEO total pay: 540474 · Pay ratio (CEO : median worker): 21:1Nuvalent, Inc.Akebia Therapeutics, Inc., CEO total pay: 5652339 · Pay ratio (CEO : median worker): 21:1Akebia Therapeutics, Inc.Kymera Therapeutics, Inc., CEO total pay: 8601747 · Pay ratio (CEO : median worker): 21:1Kymera Therapeutics, Inc.Arvinas, Inc., CEO total pay: 327724 · Pay ratio (CEO : median worker): 20:1Arvinas, Inc.Kronos Worldwide Inc, CEO total pay: 2256576 · Pay ratio (CEO : median worker): 23:1Kronos Worldwide IncSyndax Pharmaceuticals Inc, CEO total pay: 7281788 · Pay ratio (CEO : median worker): 19:1Syndax Pharmaceuticals Inc
Nuvalent, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Nuvalent, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Nuvalent, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
21:1
FY2025
vs prior FY
-4:1
from FY2024 25:1
CEO $ YoY
-21%
$540K latest
Filings shown
2
FY2024–2025
Nuvalent, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $688K - $27,535 25:1 -
2025 $540K -21% $540,474 21:1 -4:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1861560, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
21:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$540K
Companies in Industry
168
vs. Industry Median
Below
#126 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Nuvalent, Inc.: near-parity Item 402(u) ratio

Nuvalent, Inc.'s FY2025 ratio 21:1 ranks #126 of 168 Chemicals & Pharmaceuticals filers (26th percentile). the CEO earned 21× the median employee ($540,474) in FY2025.

At $540,474 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.

CEO Total Pay

$540K

FY2025 Summary Compensation, below median

Pay Ratio

21:1

Below typical

Nuvalent, Inc. in the lower Chemicals & Pharmaceuticals third

Nuvalent, Inc.'s FY2025 ratio 21:1 ranks #126 of 168 Chemicals & Pharmaceuticals filers (26th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Nuvalent, Inc.'s $540K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1278 and ratio rank #1209 split - treat 21:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$540K
Median Employee Pay
$540,474
Pay Ratio
21:1
Filing Date
2026-04-28

Company Info

Ticker
NUVL
CIK
1861560
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1861560, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Nuvalent, Inc.'s FY2025 ratio 21:1 ranks #126 of 168 Chemicals & Pharmaceuticals filers (26th percentile).

Read with Nuvalent, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.

Biohaven Ltd. · LIGHT

ABS(ceo_total_comp) peer at $529K (Δ $11K lighter vs Nuvalent, Inc.); MODEST · ELITE-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Dorchester Minerals, L.P. · LIGHT

ABS(ceo_total_comp) peer at $563K (Δ $23K heavier vs Nuvalent, Inc.); FLOOR · ELITE-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Octave Specialty Group Inc · LIGHT

ABS(ceo_total_comp) peer at $567K (Δ $26K heavier vs Nuvalent, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Tetra Technologies Inc · LIGHT

ABS(ceo_total_comp) peer at $508K (Δ $33K lighter vs Nuvalent, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Akebia Therapeutics, Inc. (SIC 28 pole)

Akebia Therapeutics, Inc. stamps FLOOR · MID$ nearest in-SIC by ABS(pay_ratio) to Nuvalent, Inc.'s FLOOR filing.
National dual ranks · #1278/#1209

Nuvalent, Inc.'s FY2025 package sits #1278 by CEO dollars and #1209 by ratio under LIGHT · FLOOR.
Ratio primer · FLOOR

Nuvalent, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Nuvalent, Inc. (CIK 1861560), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.